HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pseudoephedrine Tablets Go Behind The Counter In Oklahoma

This article was originally published in The Tan Sheet

Executive Summary

Legislation restricting the sale of pseudoephedrine tablets to licensed pharmacies was signed into law in Oklahoma on April 7 and is being considered by other states looking to adopt similar measures

You may also be interested in...



Nevada Rx PSE bill dies

Nevada state legislators May 22 rejected a proposal to require pseudoephedrine-containing products to be sold only by prescription. The bill, AB 150, did not receive the necessary two-thirds majority to pass. The Consumer Healthcare Products Association lobbied against the bill after its introduction (1"The Tan Sheet" Feb. 26, 2007, In Brief). Currently, Oklahoma and Oregon each have a state law requring prescription-only access to pseudoephedrine products (2"The Tan Sheet" April 12, 2004, p. 4 and 3"The Tan Sheet" Aug. 22, 2005, p. 5)...

Will Oklahoma Dextromethorphan Age Restriction Bill Lead The Way?

Increasing momentum in states for age restrictions on sales of dextromethorphan-containing cough/cold products could drive retail industry support for a federal bill mandating a uniform, nationwide age restriction

Oregon Pseudoephedrine Law Requires Prescription Status By July 2006

Oregon's State Board of Pharmacy is required to make all adult pseudoephedrine products prescription-only under a law signed by Gov. Kulongoski Aug. 16

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel